Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
COPD
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
- Trial name
- NCT00280371
- Testing
- Formoterol Fumarate
- Where
- 52 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dey
Chronic Respiratory Disease
Autologous Bronchial Basal Cells Transplantation for Treatment of CRD Including COPD, BE and PF
Chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), bronchiectasis (BE) or pulmonary fibrosis (PF) are usually not curable with damaged pulmonary structure and function.
- Trial name
- NCT03153800
- Testing
- bronchial basal cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Regend Therapeutics
Pulmonary Disease, Chronic Obstructive
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00475436
- Testing
- GSK573719
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this study is to compare the efficacy and safety of BCT197 when added on to standard of care in adult subjects with acute respiratory exacerbations of chronic obstructive pulmonary disease requiring…
- Trial name
- NCT02700919
- Testing
- BCT197
- Where
- 46 sites in United States, Bulgaria and 8 more
- Volunteers
- 282 people
- Sponsor
- Mereo BioPharma
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the systemic exposure and pharmacodynamics of two doses of nebulized fluticasone/formoterol combination as compared to the monocomponents.
- Trial name
- NCT00774761
- Testing
- fluticasone propionate/formoterol fumarate, fluticasone propionate, formoterol fumarate
- Where
- 12 sites in United States
- Volunteers
- 97 people
- Sponsor
- Dey
COPD, Hypercapnic Respiratory Failure
The Effects of Airtrapping on Sleep and Breathing in Non Invasive Ventilation (NIV) in COPD
15 COPD patients will be surveyed in this prospective randomized crossover pilot study concerning non invasive ventilation. Patients will be treated over 2 nights in randomized order with Ventimotion2 (Weinmann) with and without…
- Trial name
- NCT01987661
- Testing
- BIPAP ST, Airtrap
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
COPD
NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients
The goal of this observational study is to measure improvement in health related quality of life in moderate to severe COPD patients treated with Trimbow inhalation powder.
- Trial name
- RESPONSE (NCT05743608)
- Where
- 39 sites in Hungary
- Volunteers
- 1,336 people
- Sponsor
- Chiesi Hungary Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers
A single dose study with the inhaled anti-inflammatory agent PF-03715455 to establish if it has anti-inflammatory activity following a challenge with LPS.
- Trial name
- NCT01314885
- Testing
- PF-03715455, PH-797804
- Where
- 2 sites in United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug
This single and repeat increasing dose study will collect information on safety, tolerability and drug levels in the body of the CCI15106 inhalation powder.
- Trial name
- NCT03235726
- Testing
- CCI15106
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease
Study to investigate the effect of 12-week treatment with three doses (5, 25 and 75 mg) BIIL 284 BS on exercise endurance, lung function, quality of life, spontaneous sputum and safety in patients with chronic obstructive…
- Trial name
- NCT02249247
- Testing
- Low dose of BIIL 284 BS tablets, Medium dose of BIIL 284 BS tablets, High dose of BIIL 284 BS tablets
- Volunteers
- 577 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)
This is a multicentre study with a randomised, parallel group, open-label, 3-month phase IV design to assess the efficacy and tolerability of Symbicort as an add-on treatment to Spiriva compare with Spiriva alone in patients with…
- Trial name
- SECURE 1 (NCT01397890)
- Testing
- Budesonide/formoterol (Symbicort® Turbuhaler®), Tiotropium (SpirivaTM)
- Where
- 31 sites in China, Hong Kong and 3 more
- Volunteers
- 793 people
- Sponsor
- AstraZeneca
COPD, Chronic Obstructive Pulmonary Disease
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Sensorum Health (Sensorum) is conducting a pilot study to determine if Sensorum's proprietary passive sensor network can be used to identify signals of early health decompensation in subjects prior to a hospitalization for…
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, COPD Exacerbation, CHF
- Trial name
- NCT05865184
- Testing
- Data collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sensorum Health Inc.
Chronic Obstructive Pulmonary Disease
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an…
- Trial name
- NCT00739648
- Testing
- MP-376
- Where
- 39 sites in United States
- Volunteers
- 322 people
- Sponsor
- Amgen
Pulmonary Disease, Chronic Obstructive
SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT00361959
- Testing
- Tiotropium bromide 18mcg, Fluticasone propionate/ salmeterol combination 50/500mcg
- Where
- 166 sites in Austria, Belgium and 18 more
- Volunteers
- 1,270 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.
- Trial name
- NCT00640484
- Testing
- carmoterol (CHF 4226), salmeterol
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Bronchospasm
Dose-Ranging Study of A006 DPI, in Adult Asthma Patients
This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover and dose-ranging design. This study aims to evaluate the efficacy and initial safety profiles, and to identify the optimum dose of…
- Trial name
- NCT01174732
- Testing
- albuterol inhalation powder, albuterol inhalation aerosol
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients
Study compares the efficacy and safety of tiotropium + a beta agonist (procaterol) vs. tiotropium alone among patients with moderate chronic obstructive pulmonary disease
- Trial name
- NCT00394485
- Testing
- Procaterol, Tiotropium
- Where
- Philippines
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness
The main purpose of the study is to assess the burden of illness for, COPD using both patient-reported symptom burden and claims-based economic burden, among the subjects treated with single-inhaler dual therapy treatments…
- Trial name
- NCT03543176
- Testing
- UMEC/VI, FLUT/SAL, CAT
- Where
- United States
- Volunteers
- 789 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT07252908
- Testing
- TQC3721 inhalation powder
- Where
- 29 sites in China
- Volunteers
- 195 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.